← Back to Directory

Low-Dose Aspirin

Baby Aspirin, Acetylsalicylic Acid (low dose)

Visual ViewRaw Data

Meta Information

ID:low-dose-aspirin
Name:Low-Dose Aspirin
Schema Version:1.5

Alternate Names

  • Baby Aspirin
  • Acetylsalicylic Acid (low dose)

Active Compound

acetylsalicylic_acid

Intervention Type

therapeutic_agent

Delivery

Route:
oral
Scope:
  • systemic

Regulatory Status

  • us:otc_drug
  • eu:otc_drug

Indication

Focus:
  • disease_treatment
  • healthspan
Description:
Primarily for secondary prevention of cardiovascular events. Its role in primary prevention for general healthspan is now highly controversial and not recommended for most healthy adults.

Typical Protocol

  • A typical dose is 81 mg taken orally once daily.

Expected Cost Mean

Low Cost:
5
High Cost:
15
Cost Type:
monthly
Description:
Widely available generic over-the-counter medication; not typically covered by insurance for prevention.

Summary

Low-dose aspirin is an NSAID that irreversibly inhibits the COX-1 enzyme in platelets, reducing their ability to aggregate and form clots. This mechanism is effective for preventing heart attacks and strokes in individuals with established cardiovascular disease. However, for healthy individuals (primary prevention), large clinical trials have shown this benefit is offset by a significant increase in the risk of major bleeding, making its use for general healthspan extension unfavorable.

Purpose

Reduces blood clotting and inflammation to prevent cardiovascular events.

Card Summary

An over-the-counter NSAID used to prevent blood clots, but its healthspan benefit for primary prevention is now controversial due to bleeding risks.

Drug Class

nsaid

Drugs In Class

Empty Array

Impact

Score:
2.5
Justification:
Benefits for primary prevention do not outweigh significant bleeding risks in healthy individuals.

Evidence

Grade:
A
Score:
9.5
Justification:
Extensive evidence from numerous large-scale human RCTs and meta-analyses.

Safety

Score:
5.5
Justification:
Significant risk of major gastrointestinal bleeding and hemorrhagic stroke with chronic use.

Flags

  • Increased risk of major gastrointestinal bleeding, which can be life-threatening.
  • Increased risk of hemorrhagic stroke (bleeding in the brain).
  • Recent guidelines (e.g., USPSTF) advise against routine use for primary prevention in most adults.
  • Interacts with other anticoagulants (e.g., warfarin), NSAIDs, and alcohol, increasing bleeding risk.
  • Should not be taken by individuals with bleeding disorders or active ulcers.

Verdict

Not recommended for general healthspan due to significant bleeding risks.

Created

2026-05-06T22:00:27.546960Z

Ai Model

Gemini 2.5 Pro (High)